USTRx Act
Sponsored By: Senator Sheehy, Tim [R-MT]
Introduced
Summary
Creates a Chief Pharmaceutical Trade Negotiator to push back on high‑income countries' drug‑pricing and trade practices the bill says depress U.S. innovation. It would also require annual public reporting and force a 30‑day plan to respond to flagged practices that could include trade investigations.
Show full summary
- U.S. pharmaceutical manufacturers would get a dedicated USTR advocate to conduct negotiations, enforce trade agreements, and pursue actions when high‑income countries' policies limit U.S. market access or harm incentives to innovate.
- Patients and taxpayers would see annual, public reviews of World Bank‑defined high‑income countries that the bill says set non‑market prices, delay new medicines, or shift costs to the United States.
- The USTR would publish a rolling list of high‑income countries and, within 30 days of finding harmful practices, must submit a response plan to Congress that may include initiating an investigation under Title III of the Trade Act of 1974.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
New USTR drug trade office
This bill would create a Chief Pharmaceutical Trade Negotiator inside USTR. That Chief would review medicine trade policies in every World Bank "high income" country each year. USTR would have to send each report to the House Ways and Means and Senate Finance Committees and publish it online. If a country's policies meet any of six problem tests, USTR would have to submit a response plan within 30 days. The plan could include starting a trade investigation under Title III of the Trade Act of 1974. If enacted, these steps would aim to defend U.S. drug makers and could affect medicine availability or prices for U.S. patients over time.
Sponsors & CoSponsors
Sponsor
Sheehy, Tim [R-MT]
MT • R
Cosponsors
Sen. McCormick, David [R-PA]
PA • R
Sponsored 8/5/2026
Sen. Budd, Ted [R-NC]
NC • R
Sponsored 8/5/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov